Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.71M | $28.5M | $280M | $297M | $310M | $277M | $464M | $567M | $631M | $781M |
| Revenue growth | — | 1564.3% | 884.7% | 5.8% | 4.5% | -10.7% | 67.6% | 22.2% | 11.4% | 23.6% |
| Gross profit | — | — | $115M | $103M | $180M | $151M | $209M | $326M | $377M | $463M |
| Gross margin | — | — | 40.9% | 34.7% | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| Operating income | -$94.1M | -$75.4M | -$20.7M | -$23.7M | $56.2M | $17.6M | $33.3M | $167M | $170M | $180M |
| Operating margin | -5498.7% | -264.9% | -7.4% | -8.0% | 18.1% | 6.4% | 7.2% | 29.5% | 26.9% | 23.0% |
| Net income | -$94.2M | -$74.9M | -$39.1M | -$22.7M | $26.8M | $71.5M | -$25.0M | $48.2M | $69.2M | $62.9M |
| Net margin | -5504.1% | -262.9% | -14.0% | -7.7% | 8.6% | 25.8% | -5.4% | 8.5% | 11.0% | 8.1% |
| EPS (diluted) | -$3.88 | -$2.47 | -$1.19 | -$0.68 | $0.76 | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$75.1M | -$67.0M | $169M | $27.8M | $93.9M | $104M | $124M | $275M | $205M | $329M |
| Capital expenditures | $477K | $990K | $5.48M | $6.44M | $5.55M | $1.94M | $1.62M | $461K | $1.65M | $1.74M |
| Free cash flow | -$75.5M | -$68.0M | $164M | $21.3M | $88.4M | $102M | $123M | $274M | $203M | $328M |
| Share buybacks | — | — | — | — | — | $47.9M | $14.1M | $75.0M | $60.0M | $25.1M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $153M | $119M | $147M | $170M | $174M | $186M | $174M | $239M | $70.6M | $231M |
| Total assets | $162M | $136M | $291M | $306M | $644M | $692M | $1.17B | $1.14B | $1.66B | $1.66B |
| Total liabilities | $27.1M | $31.5M | $200M | $219M | $458M | $489M | $979M | $948M | $1.43B | $1.36B |
| Long-term debt | $4.15M | — | $11.5M | $11.5M | — | — | — | — | — | — |
| Shareholders' equity | $135M | $104M | $91.6M | $87.4M | $186M | $203M | $195M | $195M | $229M | $302M |
| Retained earnings | -$223M | -$298M | -$337M | -$360M | -$333M | -$256M | -$281M | -$233M | -$164M | -$101M |
| Shares (wtd avg diluted) | 29.4M | 32.8M | 33.0M | 33.5M | 35.2M | 41.0M | 33.8M | 41.8M | 40.4M | 39.7M |
Every figure is extracted from COLLEGIUM PHARMACEUTICAL, INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.